The First Annual Miami General Medical Oncology Symposium

February 22 – 24, 2019, Miami, FL

The First Annual Miami General Medical Oncology Symposium

Please note that slides are for review only and not to be repurposed or published.


Dr Porter
Chimeric Antigen Receptor (CAR) T-Cell Therapy and the General Medical Oncologist

Dr Kaufman
Targeting the Immune System in Myeloma: New CAR T Cells

Dr Neelapu
CAR T-Cell Therapy for B-Cell Lymphomas

Module 1: Colorectal and Gastric Cancer

Colorectal Cancer — Dr Fuchs

Gastric, Gastroesophageal Junction and Esophageal Cancer — Dr Enzinger


Module 2: Hepatocellular Carcinoma

Anti-VEGF-Directed Therapy — Dr El-Khoueiry

Immune Checkpoint Inhibitors — Dr Greten


Module 3: Melanoma

Adjuvant Therapy — Dr Lipson

Metastatic Disease — Dr Daud


Module 4: Chronic Lymphocytic Leukemia (CLL)

Newly Diagnosed CLL — Dr Davids

Management of Relapsed/Refractory CLL and Investigational Approaches — Dr Jain


Module 5: Hodgkin and Non-Hodgkin Lymphomas

Follicular Lymphoma — Dr Leonard

Mantle Cell Lymphoma and Hodgkin Lymphoma — Dr Moskowitz


Module 6: Ovarian Cancer (OC)

Current and Future Role of PARP Inhibitors in the Treatment of OC — Dr Coleman

Other Recently Approved and Promising Investigational Strategies — Dr Matulonis


Module 7: Pancreatic Cancer

Neoadjuvant and Adjuvant Therapy — Dr Ko

Metastatic Disease — Dr Philip


Module 8: ER-Positive, HER2-Negative Breast Cancer (BC)

Recent Clinical Trial Results Guiding the Use of Genomic Classifiers in the Management of Early BC; Ongoing Evaluation of CDK4/6 Inhibition in Earlier-Stage Disease — Dr Burstein

Sequence and Selection of Systemic Therapy for Patients with ER-Positive Metastatic BC; Novel Agents in Development — Dr Sledge


Module 9: HER2-Positive and Triple-Negative BC

Triple-Negative BC; PARP Inhibition in the Management of BC — Dr Winer

HER2-Positive Disease — Dr O’Shaughnessy


Module 10: Acute Myeloid Leukemia

Current Testing Algorithms; Treatment for Patients with a Genomic Alteration — Dr Stone

Recently Approved and Emerging Therapeutic Approaches — Dr Pollyea


Module 11: Prostate Cancer (PC)

Nonmetastatic Castration-Resistant PC (CRPC) and Metastatic Hormone-Sensitive PC — Dr Hussain

Key Issues in the Treatment of Metastatic CRPC — Dr Sartor


Module 12: Renal Cell and Bladder Cancer

Renal Cell Cancer — Dr Quinn

Urothelial Bladder Cancer — Dr Plimack


Module 13: Targeted Treatment of Lung Cancer

Management of Non-Small Cell Lung Cancer (NSCLC) with an EGFR Tumor Mutation — Dr Oxnard

Other Actionable Abnormalities in NSCLC — Dr Sequist


Module 14: Immune Checkpoint Inhibitors in Lung Cancer

Locally Advanced NSCLC; Metastatic Small Cell Lung Cancer — Dr Gubens

Metastatic NSCLC — Dr Neal


Live Poll Results



Download All

Download all slides (ZIP file)